Copyright
©The Author(s) 2018.
World J Gastroenterol. Jun 21, 2018; 24(23): 2441-2456
Published online Jun 21, 2018. doi: 10.3748/wjg.v24.i23.2441
Published online Jun 21, 2018. doi: 10.3748/wjg.v24.i23.2441
Table 10 Impact of HBsAg or HBcAb(+) grafts on HBsAg(+) living donor liver transplantation patients
| Ref. | Donor | Incidence of de novo HBV infection | Prevention of De Novo HBV infection | Study type |
| Hwang et al[129] (2006) | HBsAg(+) | NS | High-dose HBIG and lamivudine, famciclovir and interferon; a final regimen of lamivudine and adefovir | CR |
| Soejima et al[130] (2007) | HBsAg(+) | NS | lamivudine and adefovir dipivoxil | CR |
| Jeng et al[131] (2015) | HBsAg(+) | NS | Entecavir 0.5 mg once daily | RS |
- Citation: Lan X, Zhang H, Li HY, Chen KF, Liu F, Wei YG, Li B. Feasibility of using marginal liver grafts in living donor liver transplantation. World J Gastroenterol 2018; 24(23): 2441-2456
- URL: https://www.wjgnet.com/1007-9327/full/v24/i23/2441.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i23.2441